MDxHealth (NASDAQ:MDXH) vs. BioNexus Gene Lab (NASDAQ:BGLC) Head-To-Head Contrast

BioNexus Gene Lab (NASDAQ:BGLC) and MDxHealth (NASDAQ:MDXH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Volatility and Risk

BioNexus Gene Lab has a beta of 6.55, indicating that its stock price is 555% more volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BioNexus Gene Lab and MDxHealth, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	0	0	0	0	0.00
MDxHealth	0	0	4	0	3.00

MDxHealth has a consensus target price of $7.00, suggesting a potential upside of 191.67%. Given MDxHealth’s stronger consensus rating and higher probable upside, analysts clearly believe MDxHealth is more favorable than BioNexus Gene Lab.

Earnings & Valuation

This table compares BioNexus Gene Lab and MDxHealth”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$9.26 million	0.50	-$2.63 million	N/A	N/A
MDxHealth	$84.71 million	0.04	-$43.10 million	($1.52)	-1.58

BioNexus Gene Lab has higher earnings, but lower revenue than MDxHealth.

Insider & Institutional Ownership

18.9% of BioNexus Gene Lab shares are held by institutional investors. 2.0% of BioNexus Gene Lab shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares BioNexus Gene Lab and MDxHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-10.17%	-9.93%	-8.43%
MDxHealth	-49.52%	-1,077.84%	-28.82%

Summary

BioNexus Gene Lab beats MDxHealth on 8 of the 12 factors compared between the two stocks.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.